Posted On: 10/09/2015 10:16:12 AM
Post# of 72447
Probably the important part:
For instance, in this past week, Cellceutix filed an Orphan Drug application with the U.S. Food and Drug Administration (FDA) for Kevetrin for pancreatic cancer; hosted a conference call with the FDA discussing Kevetrin for retinoblastoma; engaged in a collaboration with physicians at one of the most recognizable cancer hospitals in the U.S. in writing a grant application for researching Kevetrin for pancreatic cancer; and continued advancing the protocol for a mid-stage trial of Kevetrin for ovarian cancer.
For instance, in this past week, Cellceutix filed an Orphan Drug application with the U.S. Food and Drug Administration (FDA) for Kevetrin for pancreatic cancer; hosted a conference call with the FDA discussing Kevetrin for retinoblastoma; engaged in a collaboration with physicians at one of the most recognizable cancer hospitals in the U.S. in writing a grant application for researching Kevetrin for pancreatic cancer; and continued advancing the protocol for a mid-stage trial of Kevetrin for ovarian cancer.
(0)
(0)
If you try to defend yourself against lies of the board moderators your post will be deleted. Just like the board they claim to be better than!!! Watch who you trust especially the "long term investors" that support the real attackers!
